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Background: Heat shock proteins (HSPs) are capable of promoting antigen presentation of chaperoned peptides
through interactions with receptors on antigen presenting cells. This property of HSPs suggests a potential function
as an adjuvant-free carrier to stimulate immune responses against a covalently linked fusion partner. MAGE-A1 is a
likely candidate for tumor immunotherapy due to its abundant immunogenic epitopes and strict tumor specificity.
To analyze the influence of HSP70 conjugation to MAGE-A1, towards developing a novel effective vaccine against
MAGE-expressing tumors, we cloned the murine counterpart of the human HSP70 and MAGE-A1 genes.
Methods: Recombinant proteins expressing Mage-a1 (aa 118–219), Hsp70, and Mage-a1-Hsp70 fusion were purified
and used to immunize C57BL/6 mice. The humoral and cellular responses elicited against Mage-a1 were measured
by ELISA, IFN-γ ELISPOT assay, and cytotoxicity assay.
Results: Immunization of mice with Mage-a1-Hsp70 fusion protein elicited significantly higher Mage-a1-specific
antibody titers than immunization with either Mage-a1 alone or a combination of Mage-a1 + Hsp70. The frequency
of IFN-γ-producing cells and the cytotoxic T lymphocyte (CTL) activity was also elevated. Consistent with the
elevated immune response, immunization with fusion protein induced potent in vivo antitumor immunity against
MAGE-a1-expressing tumors.
Conclusions: These results indicate that the fusion of Hsp70 to Mage-a1 can enhance immune responses and
anti-tumor effects against Mage-a1-expressing tumors. Fusion of HSP70 to a tumor antigen may greatly enhance
the potency of protein vaccines and can potentially be applied to other cancer systems with known tumor-specific
antigens. These findings provide a scientific basis for the development of a novel HSP70 and MAGE fusion protein
vaccine against MAGE-expressing tumors.
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The molecular cloning of MAGE-1 by van der Bruggen
et al. in 1991 provided a major breakthrough in identi-
fying tumor antigens recognized by host cytotoxic T-
lymphocytes (CTL). Using the melanoma cell line
MZ2-MEL and autologous CTL clones cytolytic to this
line, MAGE-1 (subsequently re-named MAGE-A1/mel-
anoma antigen A1) was identified as the target antigen
for one of the CTL clones, representing the first im-
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reproduction in any medium, provided the orCTL responses in a cancer patient [1]. Subsequent stud-
ies showed that MAGE-A1 is a member of a family (the
MAGE gene family) encoding proteins that are classi-
fied as tumor antigens, also referred to as cancer testis
(CT) antigens. These antigens are expressed by tumors
of different histological types, but are silenced in normal
cells (with the exception of the male germ-line cells of
the testis, which do not express MHC class I molecules
and are therefore incapable of presenting antigens to
CTLs). More than 100 CT antigen family proteins have
now been identified, and some of these have been
shown to be capable of eliciting immune responses [2].
Because CT antigens are immunogenic and their expres-
sion is highly restricted to tumors, they represent an
ideal target for tumor immunotherapy.td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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used in several small–scale phase I/II therapeutic vaccin-
ation trials. Patients with advanced malignancies of cuta-
neous melanoma, non–small-cell lung cancer (NSCLC)
or head and neck, esophageal, or bladder cancer were
enrolled in these trials. These trials consisted of anti-
genic peptides, protein, recombinant poxvirus-encoding
mini-genes, or dendritic cells (DCs) pulsed with anti-
genic peptide. No significant toxicity was reported; how-
ever, only a small proportion of the patients (10 to 20%)
showed evidence of tumor regression [3-7]. Therefore, it
is important to develop a more potent MAGE-A1-based
vaccine.
The combined use of heat shock proteins (HSPs) has
been explored as a strategy for enhancing vaccine po-
tency [8-15]. HSPs are a large family that includes indu-
cible and also ubiquitously and constitutively expressed
protein chaperones [10]. The effect of HSPs on immuno-
therapy was first indicated by the demonstration that
HSPs purified from tumor cells, but not normal tissues,
can immunize animals to generate tumor-specific im-
munity. The immunogenicity of the tumor-derived HSPs
was shown to be dependent on the peptides associated
with HSP molecules rather than the HSPs per se [11].
HSP-based cancer vaccines, including tumor-derived
HSP-peptide complex, artificially reconstituted HSP-
peptide complex, HSP-based DNA cancer vaccines, and
HSP fusion protein, have been widely explored in tumor
models [12]. Among these HSP preparations in different
formulations, the fusion protein strategy, which allows
covalent linkage of multiple antigenic epitopes to a sin-
gle HSP fusion protein, has been shown to be successful,
simple and feasible. The adjuvant property of mycobac-
terial HSP70 fusion protein has been extensively studied
using HIV-1 p24 [13], ovalbumin [14], influenza nucleo-
protein [15], MAGE-1 [8] and MAGE-3 [9] as model an-
tigens. In the latter two studies [8,9], a fusion protein
linking Mycobacterium tuberculosis HSP70 and a human
MAGE was used to elicit anti-tumor effects against a
mouse melanoma cell line, B16, which was transfected
into mice. Although the HSP70-MAGE fusion proteins
elicited stronger cellular and humoral immune responses
against MAGE-expressing tumors than those elicited by
MAGE protein alone, the specificity of the response
could be of concern. The use of Mycobacterial HSP70 as
an adjuvant in a murine model could elicit cross-reaction
with host HSP and thereby induce inappropriate auto-
immune responses, including autoimmune-mediated in-
testinal inflammation [16,17]. Additionally, there are likely
to be differences in the processing and presentation of hu-
man epitope peptides by the murine MHC system in this
model. Thus, the combination of proteins from different
species may impart a level of complexity in interpreting
the results. To eliminate the risk of inducing autoimmunedisorders and to reflect a more authentic murine immune
response to tumor antigens, in this study the murine
counterpart of the human HSP70 and MAGE-A1 genes
(designated Hsp70 and Mage-a1) were cloned. Prokaryotic
plasmids were constructed to express a Mage-a1 (aa 118–
219) gene segment, Hsp70, and the Mage-a1-Hsp70 fusion
protein. The recombinant proteins were expressed and
purified for immunization of mice. We demonstrate that
linkage of Hsp70 to Mage-a1 enhances the immunogenicity
of Mage-a1, which results in increased antitumor humoral
and cellular immunity against Mage-a1-expressing murine
melanoma cells.
Materials and methods
Construction of prokaryotic protein expression vectors
The sequences of the Mus musculus Hsp70 and Mage-a1
genes [GenBank: NM_010479 and NM_020015] were
used as references for primer design. Forward Primer (5’-
gaattcgccaagaacacggcgatcggcat-3’ and reverse primer 5’-
gtcgacaatccacctcctcgatggtgggt-3’) flanked respectively by
EcoR1 and Sal1 restriction sites (italics) were used to amp-
lify the coding sequence for the 2nd to the last amino acid
of the Hsp70 gene. Forward Primer (5’- ggatccaccaaagca-
gaaatgttggaaag-3’) and reverse primer (5’- gaattcaccaca-
caatcctatgttattca -3’) flanked respectively by BamH1and
EcoR1 restriction sites (italics) were used to amplify the
coding sequence of the Mage-a1gene segment (aa 118–
219). DNA extracted from liver tissue of a C57BL/6
mouse was used as template to amplify the Hsp70 and
Mage-a1 genes. The PCR products of the two segments
were first cloned separately into pGEM-T vector (Pro-
mega, USA). After verification by sequencing, recom-
binant pGEM-T vectors were digested with restriction
enzymes, and the isolated segments were separately
cloned into pGEX4T-1 to construct pGEX4T-1-Hsp70
and pGEX4T-1-Mage-a1 expression vectors. Then, the
Mage-a1 segment was inserted into BamH1- and EcoR1-
digested pGEX4T-1-Hsp70 vector to obtain the Mage-a1
(aa 118–219)/Hsp70 fusion protein expression vector,
pGEX4T-1-Mage-a1-Hsp70. All recombinant expression
vectors were verified by sequencing.
Protein expression and purification
The pGEX4T-1, pGEX4T-1-Mage-a1, pGEX4T-1-Hsp70
and pGEX4T-1-Mage-a1-Hsp70 constructs were trans-
formed into E. coli Rosetta 2 (DE3) (Novagen, USA).
Bacterial cultures were grown to OD600 ≈ 0.5, and then
protein expression was induced by adding 0.1 mM iso-
propyl β-thiogalactopyranoside (IPTG) to the growth
media. Bacteria were cultured at 32°C for 4 hours and
then harvested by centrifugation. Cell pellets were resus-
pended in PBS (4.3 mM Na2HPO4, 1.47 mM KH2PO4,
137 mM NaCl, and 2.7 mM KCl, pH 7.3) and stored fro-
zen at −20°C. Upon purification, the suspension was
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cell suspension at a final concentration of 0.1%, and lyso-
zyme was added at a final concentration of 45 kU/gram of
cell paste. Cell pellets were sonicated to suspend thor-
oughly and shear the DNA. The tubes were centrifuged at
high speed to precipitate the cellular debris while leaving
the soluble protein in the supernatant. As the target pro-
teins have a glutathione S-transferase (GST) tag, the GST ·
Band Kit (Novagen, USA), an affinity chromatography
column with GST Binding Resin was used to purify the
proteins according to the manufacturer's instructions.
Cell lines
Cells were maintained in RPMI 1640 medium supple-
mented with 10% fetal bovine serum, 100 mg/ml of
streptomycin, and 100 U/ml of penicillin in a humidified
atmosphere at 37°C with 5% CO2. A murine melanoma
cell line B16 was used to generate the B16-Mage-a1 cell
line, which stably expresses the Mus musculus Mage-a1
gene. To establish the B16-Mage-a1 cell line, the eukaryotic
expression vector pcDNA3.1-Mage-a1 was constructed and
transfected into B16 cells. Transfected cells were grown in
medium containing 600 μg/ml G418 (Sigma, USA) until
single colonies appeared. The expression of Mage-a1 in
B16-Mage-a1 was determined by RT-PCR (data not
shown).
Mice and vaccination
C57BL/6 mice were obtained from the laboratory animal
center of Sun Yat-Sen University (Guangzhou, China).
All of the mice were 6 week old females bred and main-
tained under specific pathogen-free conditions. Purified
GST, Hsp70, Mage-a1, Mage-a1-Hsp70 fusion protein,
or a combination of Mage-a1 + Hsp70 proteins, were di-
luted to 200 pmol. Six groups of mice were immunized
sub-cutaneously with 0.2 ml of each protein or PBS con-
trol, followed by a booster after 1 week. All the procedures
are in accordance with the guidelines of the laboratory
animal ethics committee of Sun Yat-sen University.
Anti-Mage-a1 ELISA
Anti-Mage-a1 antibody in the sera of vaccinated mice
was determined by ELISA. Briefly, a 96-well flat-bottom
ELISA plate was coated with 50 μl of 2.5 μg/ml Mage-a1
protein (aa 118–219) overnight at room temperature.
The plate was rinsed with PBS, incubated with blocking
buffer (5% nonfat dry milk powder and 0.2% Tween 20
in PBS) for 2 h at 37°C. Mouse serum was diluted 1:50
in blocking buffer, added to the plate, and incubated for
2 h at 37°C. After rinsing with PBS, the plate was incu-
bated with horseradish peroxidase-conjugated anti-mouse
IgG (Santa Cruz Biotech Inc., USA) for 1 h at 37°C. After
extensive washing, Tetramethyl-benzidine substrate was
added, and plates were incubated for 20 min at roomtemperature. The reactions were stopped with 2 M
H2SO4, and the ELISA plates were read at 450 nm.
IFN-γ ELISPOT
Mice were sacrificed two weeks after the immunization
booster was injected. Splenocytes were isolated using
EZ-Sep Mouse 1X Lymphocyte Separation Medium
(Dakewe, China) according to the manufacturer's in-
structions. IFN-γ production of T cell precursors was de-
termined by using the Quick Spot Mouse IFN-γ Pre-
coated ELISPOT kit (Dakewe, China) according to the
manufacturer's instructions. PVDF-bottomed 96-well
plates were pre-coated with anti-IFN-γ antibody. A total
of 200 μl of RPMI 1640 was added to each well, plates
were incubated for 10 min, and then medium was re-
moved. 5 × 105 splenocytes/well and 3 × 104 B16-Mage-a1
cells/well were added. As a positive control, 5 × 104 sple-
nocytes/well and 4 μg/ml phytohemagglutinin (PHA) were
added. As a negative control, only serum-free culture
medium was added. Plates were incubated without agita-
tion for 24 h at 37°C. Cells were then removed and bio-
tinylated IFN-γ detection antibody was added and plates
were incubated for 1 h at 37°C. Free antibody was washed
out, and plates were incubated with streptavidinalkaline
phosphatase for 1 h at 37°C, followed by 10 washes with
PBST and visualization with alkaline phosphatase sub-
strate AEC. The number of dots in each well was counted
using Biosys Bioreader 4000 PRO (Bio-sys, German). The
experiment was repeated three times.
Cytotoxicity assays
The Cytotoxic 96 nonradioactive cytotoxicity assay (Promega,
USA) was used to detect the cytotoxic activity of spleno-
cytes from mice immunized with the protein vaccines.
This assay quantitatively measures lactate dehydrogenase
(LDH), a stable cytosolic enzyme that is released upon cell
lysis. To develop the effector cells, splenocytes isolated as
in the ELISPOT assay were co-cultured with lethally irra-
diated (10000 rad of 60Co) B16-Mage-a1 cells in the pres-
ence of 40 U/ml rhIL-2 (Cytolab Ltd./Peprotech Asia,
USA) for 3 days at 37°C. According the manufacturer's in-
structions, we first optimized the number of B16-Mage-a1
target cells at 1 × 104 and then set up the 96 well assay
plate. In the experimental wells, effector cells at a ratio of
1:2.5, 1:5, and 1:10 were added to 1 × 104 target cells to a
final volume of 200 μl. The plate was incubated for
45 min at 37°C and centrifuged at 500 g for 5 min. Subse-
quently, 50 μl supernatant from each well was transferred
to a new plate, and 50 μl substrate mix was added to each
well. The plate was incubated for 30 min at room
temperature in darkness. A total of 50 μl stop solution
was added to each well, and the absorbance values were
measured at 490 nm. The cytotoxicity for each effector:
target cell ratio was calculated as [A(experimental)-A
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[A(target maximum)-A(target spontaneous)].In vivo mouse tumor challenge
For inoculation of tumor cells, cultured cells were col-
lected and washed twice in serum-free RPMI 1640. Vi-
able cells were counted using trypan blue and a cell
meter. Cell suspensions were adjusted to a concentra-
tion of 1 × 106 cells/ml, and 0.1 ml cell suspension was
inoculated sub-cutaneously in the upper flank of mice.
For tumor protection experiments, 6 groups of mice
were immunized with GST, Hsp70, Mage-a1, Mage-a1 +
Hsp70, Mage-a1-Hsp70 or the PBS control, followed by a
booster after one week. One week after the booster, mice
were challenged with 1 × 105 B16-Mage-a1 cells/mouse.
For in vivo tumor treatment experiments, another 6
groups of mice were first challenged with 1 × 105 B16-
Mage-a1 cells/mouse. At 3 days and 10 days post-tumor
cell inoculation, mice were immunized. Tumor growth
was observed every day. Tumor length and width were
measured at fixed time intervals. The tumor volume was
defined as V (V = length × width2 × 0.5), where V repre-
sents the mean value of tumors in each group. Mice were
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Figure 1 Construction of vectors and recombinant protein expression
pGEX4T1 vectors. Mage-a1 (aa118-219) gene segment, Hsp70 and Mage-a1-H
GST sequence. B. GST protein was expressed by the vector pGEX4T-1 in E. col
lysate without and with IPTG induction. Lane 3, purified GST protein. C. Mage
protein molecular weight markers. Lanes 1–2, whole cell lysate without and w
loading concentration. D. Hsp70 and Mage-a1-Hsp70 protein expressed by re
protein molecular weight markers. Lanes 1–2, whole cell lysate of E. coli Roset
Lanes 3–4, purified Hsp70 protein at 1× or 2× loading concentration.
pGEX4T-1-Mage-a1-Hsp70 without and with IPTG induction. Lanes 7–8, purifieStatistical analysis
All statistical analyses were carried out using Graphpad
Prism 5 software for Windows. Results are presented as
mean ± standard error (SE). Data were analyzed by one-
way analysis of variance (ANOVA) and two-way ANOVA.
P values < 0.05 were considered statistically significant.
Results
Expression and purification of recombinant proteins
To determine whether fusion of Mage-a1 to Hsp70 can in-
crease the potency of vaccination against Mage-expressing
tumors, we expressed Mus musculus Mage-a1, Hsp70, and
Mage-a1-Hsp70 fusion proteins using the prokaryotic ex-
pression vector pGEX4T1, which produces GST-tagged
recombinant proteins (Figure 1A). Only part of the Mage-
a1 coding sequence (aa 118–219) was cloned because full
length Mage-a1 failed to produce detectable protein after
IPTG induction. High level protein expression was in-
duced by IPTG for the control pGEX4T1 vector and the
three GST tagged vectors in E. coli Rosetta 2 (DE3) cells,
and the proteins were purified by GST affinity chromatog-
raphy (Figure 1B-D). A single predominate band of ex-
pected size of the purified protein was isolated for each of
these proteins, though additional faint bands could be ob-
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and purification. A. Schematic representation of recombinant
sp70 fusion gene were cloned into pGEX4T1 vector downstream of the
i Rosetta 2. M, protein molecular weight markers. Lanes 1–2, whole cell
-a1 protein expressed by recombinant vector pGEX4T-1-Mage-a1. M,
ith IPTG induction. Lanes 3–4, purified Mage-a1 protein at 2× or 1×
combinant vector pGEX4T-1-Hsp70 and pGEX4T-1-Mage-a1-Hsp70. M,
ta 2 transformed with pGEX4T-1-Hsp70 without and with IPTG induction.
Lanes 5–6, whole cell lysate of E. coli Rosetta 2 transformed with
d Mage-a1-Hsp70 protein at 1× or 2× loading concentration.
Figure 2 Humoral immune response after vaccination with
Hsp70-Mage-a1 fusion protein. Purified GST, Hsp70, Mage-a1,
Mage-a1-Hsp70 fusion protein or a combination of Mage-a1 +
Hsp70, were diluted to a concentration of 200 pmol. Mice were
immunized sub-cutaneously with a PBS control or 0.2 ml of each
protein, followed by a booster injection after one week. Serum
samples were obtained two weeks after the booster. The levels of
anti-Mage-a1 antibody were examined by ELISA. The means ± SE of
the absorbance (A540 nm) of three separate experiments are
presented at 1:50 dilution. Statistical analysis by one-way ANOVA
showed that mice vaccinated with Mage-a1-Hsp70 had significantly
higher titers of anti Mage-a1 antibody than Mage-a1 or Mage-a1 +
Hsp70 (* p < 0.001).
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attempt to remove the GST tag of the recombinant pro-
tein before use in the vaccine experiment, we digested the
proteins with thrombin; however, recombinant Hsp70
protein was cut to several bands after thrombin digestion,
potentially due to nonspecific thrombin cleavage recogni-
tion sites in the Hsp70 sequence (data not shown). There-
fore, the GST tags in the recombinant proteins were not
removed, and instead, a GST control group was added to
our experiments to exclude the effects of the GST tag or
common contaminants.
Enhanced induction of Mage-a1-specific humoral immune
responses by fusion of Mage-a1 with Hsp70
To examine the immune response elicited by the puri-
fied proteins, six groups of mice were injected sub-
cutaneously with GST, Hsp70, Mage-a1, Mage-a1-Hsp70
or Mage-a1 + Hsp70 (1:1 mixture). Mice were also
injected with 0.2 ml PBS as an additional control. One
week later, a booster vaccine was administered, and two
weeks after the booster, the quantity of anti-Mage-a1
antibody in the sera of the vaccinated mice was deter-
mined by ELISA. Mice vaccinated with PBS control,
GST and Hsp70 proteins showed low or undetectable
levels of anti Mage-a1 antibody. In contrast, mice vacci-
nated with Mage-a1, Mage-a1 + Hsp70, and Mage-a1-
Hsp70 had elevated levels of anti-Mage-a1 antibody. Of
these three, the mice vaccinated with Mage-a1-Hsp70
fusion protein produced the highest levels of anti-Mage-
a1 antibody (Figure 2). These results verify that Mage-a1
fusion to Hsp70 leads to an elevated humoral immune
response against Mage-a1.
Enhanced induction of T-cell-mediated Mage-a1-specific
immune responses by fusion of Mage-a1 with Hsp70
To determine whether mice can induce T-cell-mediated
Mage-a1-specific immune responses after vaccination
with Mage-a1-Hsp70, mice were immunized and the
splenocytes were harvested and pooled two weeks after
administration of the booster. B16-Mage-a1-specific
IFN-γ production of T cell precursors was determined
by ELISPOT assay, which is a sensitive functional assay
used for the identification and enumeration of cytokine-
producing cells at the single cell level. As shown in
Figure 3A, very few spot-forming T cell precursors were
observed in the splenocytes from mice injected with
PBS, GST or Hsp70 control proteins. However, there
were many more spot-forming T cell precursors in the
splenocytes from mice injected with Mage-a1, Mage-a1 +
Hsp70, and Mage-a1-Hsp70 fusion protein. Moreover,
the number of spot-forming cells in the Mage-a1-Hsp70
group was higher than the Mage-a1 and Mage-a1 +Hsp70 groups. This result suggests that Mage-a1 can
elicit B16-Mage-a1-specific IFN-γ production by splenic
T cell precursors, but that the Mage-a1-Hsp70 fusion
protein has a stronger effect than Mage-a1 alone or
Mage-a1 separately combined with Hsp70.
To assess whether B16-Mage-a1-specific CTLs are in-
duced in immunized mice, splenocytes were also as-
sesses by cytotoxicity assay. Effector cells were obtained
by co-culture of splenocytes with lethally irradiated B16-
Mage-a1 cells at increasing ratios. As shown in Figure 3B.
The percentage of CTLs undergoing B16-Mage-a1-spe-
cific lysis was less than 10% in splenocytes from mice
injected with PBS control, GST and Hsp70 proteins.
However, splenocytes from mice injected with Mage-a1,
Mage-a1 + Hsp70 and Mage-a1-Hsp70 showed higher
levels of lysis than the controls. Furthermore, the Mage-
a1-Hsp70 group promoted more CTL lysis than the
Mage-a1 and Mage-a1 + Hsp70 groups. Together, these
results suggest that Mage-a1 vaccine can induce Mage-
a1-specific T-cell-mediated immune responses and that
the fusion of Mage-a1 with Hsp70 protein can enhance
this effect.
Figure 3 T-cell-mediated immune response after vaccination with Hsp70-Mage-a1 fusion protein. C57BL/6 mice were immunized with
purified GST, Hsp70, Mage-a1, Mage-a1-Hsp70 fusion protein or Mage-a1 + Hsp70 and then administered a booster immunization after one week.
Two weeks after the booster, pooled splenocyte cultures were prepared and re-stimulated. A. IFN-γ-producing T cells in splenocytes of immunized
mice were quantified by using ELISPOT. Data are presented as mean ± SE of three separate experiments. Statistical analysis by one-way ANOVA
revealed that mice vaccinated with Mage-a1-Hsp70 generated more IFN-γ spots than Mage-a1 or Mage-a1 + Hsp70 (* p < 0.001). B. The CTL response
induced in splenocytes of immunized mice was determined by using CytoTox 96 nonradioactive cytotoxicity assay. Data are presented as mean ± SE
of three separate experiments. Statistical analysis by two-way ANOVA revealed that Mag-a1-specific lysis of CTLs from mice vaccinated with Mage-a1-Hsp70
was higher than those vaccinated with Mage-a1 or Mage-a1 + Hsp70 at all effector: target cell ratios (* p < 0.001).
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protein confers protection against Mage-a1-expressing
tumors
To further verify the immune response induced by Mage-
a1-Hsp70 fusion protein, in vivo tumor protection was in-
vestigated in C57BL/6 mice. One week after the booster,
mice were challenged with B16-Mage-a1 cells. The PBS
control mice and mice vaccinated with GST and Hsp70
proteins developed measureable tumors starting at 13 days
after the tumor cell challenge (Figure 4A). However, 100%
of mice vaccinated with the Mage-a1-Hsp70 fusion pro-
tein remained tumor-free until 19 days after challenge,
whereas mice vaccinated with Mage-a1 and Mage-a1 +
Hsp70 remained tumor-free until 16 days after challenge.
Mage-a1 containing vaccines also induced a significant
growth repression for tumors that developed subse-
quently, with Mage-a1-Hsp70 fusion protein showing a
stronger effect than Mage-a1 and Mage-a1 + Hsp70
(Figure 4B). Therefore, Mage-a1-Hsp70 fusion protein
both delays the development of tumors and represses
the growth of Mage-a1-expressing tumors in vaccinated
mice.Therapeutic immunization with the Mage-a1-Hsp70 fusion
protein confers protection against the progression of
established tumors
Given that immunization of mice with the Mage-a1-
Hsp70 fusion protein conferred protection against chal-
lenge with B16-Mage-a1 cells, we further investigated
whether immunization with Mage-a1-Hsp70 fusion pro-
tein could block the progression of pre-established tumors.
C57BL/6 mice were injected with 1 × 105 B16-Mage-a1
cells. At 3 and 10 days post-tumor cell inoculation, mice
were immunized, and tumor development was assessed
every 3 days thereafter. The mice vaccinated with PBS,
GST or Hsp70 control proteins developed tumors starting
at 13 days after the tumor cell challenge (Figure 5A).
However, 100% of mice receiving Mage-a1-Hsp70 fusion
protein vaccination remained tumor-free 16 days after
the tumor cell challenge, whereas only 62.5% and 75%
mice receiving Mage-a1 and Mage-a1 + Hsp70 vaccin-
ation remained tumor-free. The tumor growth also was
repressed in mice vaccinated with Mage-a1, Mage-a1-
Hsp70 and Mage-a1 + Hsp70 compared to vaccination
with PBS and the other control proteins (Figure 5B),
Figure 4 Prophylactic immunization with Mage-a1-Hsp70 fusion protein protects mice against B16-Mage-a1 tumor cell challenge.
C57BL/6 mice were immunized with purified GST, Hsp70, Mage-a1, Mage-a1-Hsp70 fusion protein or Mage-a1 + Hsp70 and then administered a
booster immunization after one week. A week after the booster, the mice were challenged with 1 × 105 B16-Mage-a1 melanoma cells. A. The
tumor free status of mice was recorded as the percentage of mice remaining tumor-free every three days after tumor challenge. B. Tumor growth
was recorded as the mean tumor volume (in mm3). Error bars depict the SE, n = 8 mice/group. Statistical analysis by two-way ANOVA revealed
that from days 31 to 37 vaccination with Mage-a1-Hsp70 significantly delayed tumor growth in the B16-Mage-a1 tumor model compared to
vaccination with Mage-a1 or Mage-a1 + Hsp70 (* p < 0.01).
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lactic immunization (Figure 4B). Nevertheless, these re-
sults suggest that the Mage-a1-Hsp70 fusion protein
has protective effects both for prophylactic and thera-
peutic immunization against Mage-a1-expressing tu-
mors in mice.
Discussion
Because the MAGE-A1 antigens are shared by many tu-
mors and because of their strict tumor specificity, they
are of particular interest for cancer immunotherapy.
The MAGE-A1 gene encodes several antigenic peptides
that bind to HLA class I or class II molecules and areFigure 5 Therapeutic immunization with the Mage-a1-Hsp70 fusion p
tumors. Mice were challenged with 1 × 105 B16-Mage-a1 cells. At 3 and 10
GST, Hsp70, Mage-a1, Mage-a1-Hsp70 fusion protein or a combination of M
percentage of mice remaining tumor free after tumor challenge. B. Tumor
depict the SE, n = 8 mice/group. Statistical analysis by two-way ANOVA rev
growth in the B16-Mage-a1 tumor model compared to vaccination with Mrecognized by T lymphocytes on tumor cells [18-20].
These antigens have been used for small-scale thera-
peutic vaccination trials of cancer patients [3-7]. How-
ever, generally, the induced immune response is weak,
necessitating the development of other immunization
approaches to increase the efficacy of the vaccines.
Heat shock proteins have demonstrated increasingly
more effective use as adjuvants in the immunotherapy of
malignant tumors and infectious diseases. Antigen fusion
with hsp70 has proven powerful as a strategy to increase
the immunogenicity of a conjugated protein [9,13-15]. To
study the adjuvant property of HSP70 fusion in enhancing
a MAGE-A1-based vaccine in a preclinical mouse model,rotein confers protection against the progression of established
days post-tumor cell inoculation, mice were immunized with purified
age-a1 + Hsp70. A. The tumor free status of mice was recorded as the
growth was recorded as the mean tumor volume (in mm3). Error bars
ealed that vaccination with Mage-a1-Hsp70 significantly delayed tumor
age-a1 or Mage-a1 + Hsp70 from days 31 to 37 (* p < 0.05).
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purified recombinant Mage-a1, Hsp70, and Mage-a1-
Hsp70 fusion proteins. The choice of using Mage-a1-
Hsp70 recombinant fusion protein for immunization was
based on several theoretical advantages over vaccines con-
sisting of commonly used “short” peptides. First, after be-
ing taken up, processed, and presented by professional
APCs, Mage-a1 long proteins are much more likely to
elicit an integrated immune response consisting of a var-
iety of CD4+, CD8+, and B cell responses [21,22]. Second,
it is likely that protein vaccination leads to the presenta-
tion of epitopes that can be presented by a variety of HLA
alleles, and therefore this type of vaccine should be applic-
able to any patient regardless of HLA restriction. In
addition, the fused Hsp70 protein can activate professional
antigen-presenting cells (APCs) and cross-present chaper-
oned antigenic peptides to MHC class I molecules to gen-
erate specific cytotoxic T-lymphocytes [23].
The fusion proteins were purified to high homogeneity;
however, faint lower molecular weight bands in each puri-
fication reaction suggests a possibility that some effects
may be due to degraded recombinant proteins, or possibly
contaminants. However, the addition of several controls,
including PBS alone, vector alone, and each protein either
alone or purified separately and then combined, provides
verification of our results. Furthermore, our results are
consistent with two other studies involving HSP70-MAGE
fusions of mixed species origin [8,9]. In the latter studies a
fusion protein composed of Mycobacterium tuberculosis-
derived HSP70 (MtHSP70) and human-derived MAGE
was injected into mice; whereas this study tested a fusion
protein composed of murine Hsp70 and murine Mage-a1
in mice. The use of a same-species proteins may be advan-
tageous for several reasons: first, the use of murine-
derived protein in a mouse model may reduce the risk of
inducing autoimmune disease; second, the affinity of
murine-derived Hsp70 to Hsp70 receptors on mouse DCs
is likely to be higher than the corresponding affinity of
MtHSP70; and third, the murine MHC system may more
effectively process and present epitope peptides of murine
tumor antigens than antigens from human tumors. There-
fore, our study both confirms and extends the previous
findings by providing a more authentic model.
After the mice were immunized with the protein vac-
cine, we observed both humoral and cellular immune re-
sponses. The humoral response was determined by
measuring the quantity of anti-Mage-a1 antibody in the
sera of vaccinated mice. The cellular response was deter-
mined by measuring B16-Mage-a1-specific IFN-γ pro-
duction by T cell precursors and B16-Mage-a1-specific
CTLs from splenocytes of immunized mice. We demon-
strated that mice immunized with GST, Hsp70 protein
or PBS control have low or undetectable levels of anti-
Mage-a1 antibody in sera, minimal IFN-γ production ofT cell precursors from splenocytes, and low-level activa-
tion of B16-Mage-a1-specific CTL lysis. Compared with
GST, Hsp70 protein or PBS controls, vaccination with
Mage-a1, Mage-a1 + Hsp70, and Mage-a1-Hsp70 fusion
protein enhanced both the humoral and cellular re-
sponse, as indicated by elevated serum Mage-a1-specific
antibody, increased Mage-a1-specific IFN-γ production
and CTL cytotoxicity. Moreover, Mage-a1-Hsp70 fusion
protein vaccine induced a more dramatic response than
Mage-a1 or Mage-a1 + Hsp70. Though the effect of fu-
sion was more obvious for the cellular response than for
the humoral response, it is likely that an interplay be-
tween these two immune responses contributes to the
vaccine efficacy of Mage-a1-Hsp70. Similar to our find-
ings with Mage-a1, fusion of murine Hsp70 with Han-
taan virus nucleocapsid protein (HTNV NP) enhances
both the humoral and cellular response to the HTNV
NP, but the effects on the cellular response are more ob-
vious [24]. Further study is needed to determine the
relative contribution of the humoral response to the ef-
ficacy of the Mage-a1-Hsp70 vaccine.
Consistent with the immune responses, in vivo tumor
protection by vaccination was demonstrated by prophylactic
immunization. B16 tumor xenografts in mice immunized
with Mage-a1, Mage-a1 +Hsp70, and Mage-a1-Hsp70 fu-
sion protein grew significantly slower than that in mice
immunized with GST, Hsp70 protein or PBS control. The
tumor size of mice immunized with Mage-a1-Hsp70 fu-
sion protein was also much smaller than that of Mage-a1
and Mage-a1 + Hsp70-immunized mice. In addition, we
demonstrated that therapeutic immunization can delay
the progression of established tumors, though this effect
was decreased compared with the prophylactic immu-
nization. This result suggests that Mage-a1-Hsp70 fusion
protein is more proficient at inhibiting tumor develop-
ment when used earlier in the progression of cancer, sug-
gesting a preferential application for using this vaccine
to prevent tumor recurrence in postoperative cancer
patients.
The pro-immune effects of HSPs may be related to
their molecular properties as intracellular stress proteins.
In addition to their involvement in the degradation path-
way of cellular proteins during stress condition, HSPs fa-
cilitate the correct folding of newly synthesized proteins
and are also directly involved in the translocation of pro-
teins across membranes into different cellular compart-
ments [11,25-27]. After exiting the cell and entering the
extracellular environment, peptides chaperoned by heat
shock proteins can be taken up by antigen-presenting
cells (APCs), such as macrophages and DCs. In the cyto-
sol, the associated peptides are cross-presented via en-
dogenous MHC class-I and exogenous MHC class-II
pathways [28-30]. Several receptors for HSPs, have been
described on APCs, such as CD14 [31], CD40 [32,33],
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(SR-A) [37], Lox-1 [38] and the Toll-like receptors
(TLRs) 2 and 4 [39]. Binding of HSPs to these receptors
could promote the maturation and activation of DCs by
stimulating DCs to express MHC class II molecules or
to secrete cytokines and chemokines [33,40]. As a conse-
quence of the dual function of this chaperone-peptide
presentation on MHC class-I and -II molecules, as well
as its adjuvant property, efficient peptide-specific T-cell
stimulation is achieved. Antigen-HSP70 fusion proteins
can generate specific CD8+ T cells responses independ-
ent of CD4+ T cell help [41,42]. A possible mechanism
for this ability is the activation of DCs to release proin-
flammatory cytokines, as well as the intrinsic molecular
chaperone function of HSP70. Endogenous IL-2 also
probably plays an important role in this process. These
functions of HSPs may explain the enhanced potency of
Mage-a1 when fused to Hsp70.
MAGE-A1 is expressed in diverse histological types of
primary and metastatic tumors, such as melanoma, blad-
der, breast, prostate, and non-small cell lung cancers
[43]. The expression on tumors of most histological ori-
gins supports the use of the MAGE-A1-HSP70 fusion
protein in vaccines for a wide range of cancers express-
ing MAGE-A1. The strict tumor specificity of this anti-
gen should minimize the damage to normal tissues
following immunization. In addition, several MAGE-A1
epitopes recognized by T cells have been identified.
Those epitopes can be presented by HLA-A1, A2, A3,
A68, B37, B7, B35, B37, B53, and B57, making MAGE-
A1-HSP70 fusion protein vaccine available for most (up
to 87%) of the HLA types [18-20,44].
The MAGE-A family consists of several subtypes, in-
cluding MAGE-A1 to MAGE-A12. Although they are
expressed by many histologically different neoplasias,
individual MAGE-A expression varies among tumor
types [45]. However, the theoretical frequency by which
cancer cells express at least one of the MAGE-A anti-
gens is reported to be very high [46,47]. Because we
have successfully produced a Mage-a1 and Hsp70 fusion
protein vaccine and have demonstrated the efficacy of
this strategy in increasing the anti tumor immunogen-
icity against Mage-a1-expressing tumors, we can apply
this strategy to other subtypes of MAGE-A to expand
the number of patients eligible for MAGE-A and HSP70
fusion protein immunotherapy. To reach an optimal
anti-tumor effect for cancer patients, a mixed vaccine
with multiple MAGE-A-HSP70 fusion proteins will be
desirable.
Conclusions
In summary, our results indicate that Mage-a1-Hsp70
fusion protein can elicit stronger Mage-a1-specific im-
mune responses and antitumor effects against Mage-a1-expressing tumor than Mage-a1 alone or a combination of
Mage-a1 +Hsp70. Thus, HSP70 fusion represents a novel
and potentially promising strategy to design MAGE-based
vaccines for achieving protective immunity against malig-
nant tumors that express MAGE antigen.
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